Effects of an endothelin receptor antagonist on a model of hypertensive retinopathy

Ophthalmic Research

Volumn 43, Issue 2, 2010, Pages 99-107

  McDonald, Louise ^a   Lee, Graham R ^a   Degooyer, Tanyth E ^a   McDonald, Denise ^a   Canning, Paul ^a   Kelso, Elizabeth J ^a   McDermott, Barbara J ^a   Stitt, Alan W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bosentan; Endothelin; Hypertensive retinopathy; Microvasculature; Retina

Indexed keywords

BASEMENT MEMBRANE PROTEIN; BOSENTAN; COLLAGEN TYPE 4; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN CONVERRTING ENZYME 1; FIBRONECTIN; LAMININ BETA1; MEMBRANE PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERTENSION; HYPERTENSION RETINOPATHY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA BLOOD VESSEL; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ASPARTIC ACID ENDOPEPTIDASES; BASEMENT MEMBRANE; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HYPERTENSION; MALE; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; RETINAL DISEASES; RETINAL VESSELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES;

EID: 70349890161     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000247594     Document Type: Article

References (53)

1. Wong TY, Hubbard LD, Klein R, Marino EK, Kronmal R, Sharrett AR, Siscovick DS, Burke G, Tielsch JM: Retinal microvascular abnormalities and blood pressure in older people: The Cardiovascular Health Study. Br J Ophthalmol 2002; 86: 1007-1013.
2. Ashton N, Peltier S, Garner A: Experimental hypertensive retinopathy in the monkey. Trans Ophthalmol Soc UK 1969; 88: 167-186.
3. Garner A, Ashton N, Tripathi R, Kohner EM, Bulpitt CJ, Dollery CT: Pathogenesis of hypertensive retinopathy: an experimental study in the monkey. Br J Ophthalmol 1975; 59: 3-44.
4. Crook ED: The role of hypertension, obesity, and diabetes in causing renal vascular disease. Am J Med Sci 1999; 317: 183-188.
5. Klein R, Klein BE, Moss SE: The relation of systemic hypertension to changes in the retinal vasculature: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 1997; 95: 329- 348; discussion 348-350.
6. Kawamura H, Oku H, Li Q, Sakagami K, Puro DG: Endothelin-induced changes in the physiology of retinal pericytes. Invest Ophthalmol Vis Sci 2002; 43: 882-888.
7. Webb DJ, Strachan FE: Clinical experience with endothelin antagonists. Am J Hypertens 1998; 11: 71S-79S.
8. Persson PB: Renal blood flow autoregulation in blood pressure control. Curr Opin Nephrol Hypertens 2002; 11: 67-72.
9. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-732. (Pubitemid 120015147)
10. Rich S, McLaughlin VV: Endothelin receptor blockers in cardiovascular disease. Circulation 2003; 108: 2184-2190.
11. McDonald D, Bailie J, Archer D, Chakravarthy U: Molecular characterization of endothelin receptors and the effect of insulin on their expression in retinal microvascular pericytes. J Cardiovasc Pharmacol 1995; 26(suppl 3):S287-S289.
12. Torbidoni V, Iribarne M, Ogawa L, Prasanna G, Suburo AM: Endothelin-1 and endothelin receptors in light-induced retinal degeneration. Exp Eye Res 2005; 81: 265-275.
13. Meyer P, Flammer J, Luscher TF: Endothelium- dependent regulation of the ophthalmic microcirculation in the perfused porcine eye: role of nitric oxide and endothelins. Invest Ophthalmol Vis Sci 1993; 34: 3614-3621.
14. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, Burri K, Cassal JM, Hirth G, Muller M, Neidhart W, et al: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-235.
15. Li JS, Lariviere R, Schiffrin EL: Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate- salt hypertensive rats. Evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24: 183-188.
16. Krum H, Liew D: Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. Curr Opin Investig Drugs 2003; 4: 298-302.
17. Spiers JP, Kelso EJ, Siah WF, Edge G, Song G, McDermott BJ, Hennessy M: Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J Hypertens 2005; 23: 1717-1724.
18. Doggrell SA: The therapeutic potential of endothelin-1 receptor antagonists and endothelin- converting enzyme inhibitors on the cardiovascular system. Exp Opin Investig Drugs 2002; 11: 1537-1552.
19. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM: Endothelin-1 gene expression and vascular hypertrophy in DOCA-salt hypertension compared to spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 22:S188-S190.
20. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S: Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia 1999; 42: 1228-1234.
21. Evans T, Deng DX, Chen S, Chakrabarti S: Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes 2000; 49: 662-666.
22. Chen S, Khan ZA, Cukiernik M, Chakrabarti S: Differential activation of NF- κ b and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol Endocrinol Metab 2003; 284: E1089-E1097.
23. Feeney SA, Simpson DA, Gardiner TA, Boyle C, Jamison P, Stitt AW: Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. Invest Ophthalmol Vis Sci 2003; 44: 839-847.
24. Simpson DA, Feeney S, Boyle C, Stitt AW: Retinal VEGF mRNA measured by SYBR green I fluorescence: a versatile approach to quantitative PCR. Mol Vis 2000; 6: 178-183.
25. Malik KJ, Chen CD, Olsen TW: Stability of RNA from the retina and retinal pigment epithelium in a porcine model simulating human eye bank conditions. Invest Ophthalmol Vis Sci 2003; 44: 2730-2735.
26. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H: Advanced glycation end products (AGEs) co-localize with age receptors in the retinal vasculature of diabetic and of age-infused rats. Am J Pathol 1997; 150: 523-531.
27. Bell D, Kelso EJ, Argent CC, Lee GR, Allen AR, McDermott BJ: Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat. Cardiovasc Pathol 2004; 13: 71-78.
28. Bing OH, Conrad CH, Boluyt MO, Robinson KG, Brooks WW: Studies of prevention, treatment and mechanisms of heart failure in the aging spontaneously hypertensive rat. Heart Fail Rev 2002; 7: 71-88.
29. Adams MA, Bobik A, Korner PI: Differential development of vascular and cardiac hypertrophy in genetic hypertension: relation to sympathetic function. Hypertension 1989; 14: 191-202.
30. Li JS, Schiffrin EL: Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension 1995; 25: 495-500.
31. Tsotetsi OJ, Woodiwiss AJ, Netjhardt M, Qubu D, Brooksbank R, Norton GR: Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. Hypertension 2001; 38: 846-851.
32. Clozel M: Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol 2000; 35:S65-S68.
33. Roux S, Qiu C, Sprecher U, Osterwalder R, Clozel JP: Protective effects of endothelin receptor antagonists in dogs with aortic crossclamping. J Cardiovasc Pharmacol 1999; 34: 199-205. (Pubitemid 29350500)
34. Fluckiger W, Perrin IV, Rossi GL: Morphometric studies on retinal microangiopathy and myocardiopathy in hypertensive rats (SHR) with induced diabetes. Virchows Arch B Cell Pathol Incl Mol Pathol 1984; 47: 79-94.
35. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski AS, Chachich M, Baynes JW, Thorpe SR, Anderson NL: The age inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-2832.
36. Intengan HD, Thibault G, Li JS, Schiffrin EL: Resistance artery mechanics, structure, and extracellular components in spontaneously hypertensive rats: effects of angiotensin receptor antagonism and converting enzyme inhibition. Circulation 1999; 100: 2267-2275.
37. Saouaf R, Takasaki I, Eastman E, Chobanian AV, Brecher P: Fibronectin biosynthesis in the rat aorta in vitro: changes due to experimental hypertension. J Clin Invest 1991; 88: 1182-1189.
38. Intengan HD, Schiffrin EL: Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.
39. Chen S, Khan ZA, Karmazyn M, Chakrabarti S: Role of endothelin-1, sodium hydrogen exchanger-1 and mitogen-activated protein kinase (MAPK) activation in glucose- induced cardiomyocyte hypertrophy. Diabetes Metab Res Rev 2007; 23: 356-367.
40. Schiffrin EL: State-of-the-art lecture: role of endothelin-1 in hypertension. Hypertension 1999; 34: 876-881.
41. Gomez-Garre D, Largo R, Liu XH, Gutierrez S, Lopez-Armada MJ, Palacios I, Egido J: An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 1996; 50: 962-972.
42. Sanchez R, MacKenzie A, Farhat N, Nguyen TD, Stewart DJ, Mercier I, Calderone A, Thorin E: Endothelin B receptor-mediated regulation of endothelin-1 content and release in cultured porcine aorta endothelial cell. J Cardiovasc Pharmacol 2002; 39: 652-659.
43. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S: Diabetes-induced myocardial structural changes: role of endothelin-1 and its receptors. J Mol Cell Cardiol 2000; 32: 1621-1629.
44. Uddman E, Adner M, Edvinsson L: Protein kinase C inhibitors decrease endothelin ET B receptor mRNA expression and contraction during organ culture of rat mesenteric artery. Eur J Pharmacol 2002; 452: 215-222.
45. Saito S, Hirata Y, Imai T, Marumo F: Autocrine regulation of the endothelin-1 gene in rat endothelial cells. J Cardiovasc Pharmacol 1995; 26(suppl 3):S84-S87.
46. Uchida K, Uchida S, Nitta K, Yumura W, Nihei H: Regulated expression of endothelinconverting enzymes in glomerular endothelial cells. J Am Soc Nephrol 1997; 8: 580-585.
47. Rizvi MA, Katwa L, Spadone DP, Myers PR: The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol 1996; 28: 243-252.
48. De Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, Warner TD, Vane JR: Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85: 9797-9800.
49. Roberts R, Luan H, Berkowitz BA: Blocking ET-1 receptors does not correct subnormal retinal oxygenation response in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci 2006; 47: 3550-3555. (Pubitemid 351639723)
50. Hamet P, Richard L, Dam TV, Teiger E, Orlov SN, Gaboury L, Gossard F, Tremblay J: Apoptosis in target organs of hypertension. Hypertension 1995; 26: 642-648.
51. Dickhout JG, Lee RM: Apoptosis in the muscular arteries from young spontaneously hypertensive rats. J Hypertens 1999; 17: 1413-1419.
52. Cattaruzza M, Dimigen C, Ehrenreich H, Hecker M: Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells. FASEB J 2000; 14: 991-998.
53. Houben AJ, Canoy MC, Paling HA, Derhaag PJ, de Leeuw PW: Quantitative analysis of retinal vascular changes in essential and renovascular hypertension. J Hypertens 1995; 13: 1729-1733.